ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A DNA-Methylation-Driven Genes Based Prognostic Signature Reveals Immune Microenvironment in Pancreatic Cancer

Xiao, Mingjia; Liang, Xiangjing; Yan, Zhengming; Chen, Jingyang; Zhu, Yaru; Xie, Yuan; Li, Yang; Li, Xinming; Gao, Qingxiang; Feng, Feiling*; Fu, Gongbo*; Gao, Yi*南方医科大学; 南京大学; 1; y
Frontiers in Immunology2022-2-10DOI: 10.3389/fimmu.2022.803962
13被引20阅读
引用收藏
分享

摘要

Pancreatic cancer (PACA), which is characterized by an immunosuppressive nature, remains one of the deadliest malignancies worldwide. Aberrant DNA methylation (DNAm) reportedly influences tumor immune microenvironment. Here, we evaluated the role of DNA methylation driven genes (MDGs) in PACA through integrative analyses of epigenomic, transcriptomic, genomic and clinicopathological data obtained from TCGA, ICGC, ArrayExpress and GEO databases. Thereafter, we established a four-MDG signature, comprising GPRC5A, SOWAHC, S100A14, and ARNTL2. High signature risk-scores were associated with poor histologic grades and late TNM stages. Survival analyses showed the signature had a significant predictive effect on OS. WGCNA revealed that the signature may be associated with immune system, while high risk-scores might reflect immune dysregulation. Furthermore, GSEA and GSVA revealed significant enrichment of p53 pathway and mismatch repair pathways in high risk-score subgroups. Immune infiltration analysis showed that CD8+ T cells were more abundant in low score subgroups, while M0 macrophages exhibited an opposite trend. Moreover, negative regulatory genes of cancer-immunity cycle (CIC) illustrated that immunosuppressors TGFB1, VEGFA, and CD274 (PDL1) were all positively correlated with risk-scores. Furthermore, the four signature genes were negatively correlated with CD8+ lymphocytes, but positively associated with myeloid derived suppressor cells (MDSC). Conversely, specimens with high risk-scores exhibited heavier tumor mutation burdens (TMB) and might show better responses to some chemotherapy and targeted drugs, which would benefit stratification of PACA patients. On the other hand, we investigated the corresponding proteins of the four MDGs using paraffin-embedded PACA samples collected from patients who underwent radical surgery in our center and found that all these four proteins were elevated in cancerous tissues and might serve as prognostic markers for PACA patients, high expression levels indicated poor prognosis. In conclusion, we successfully established a four-MDG-based prognostic signature for PACA patients. We envisage that this signature will help in evaluation of intratumoral immune texture and enable identification of novel stratification biomarkers for precision therapies.

学科与关键词

关键词
pancreatic cancerDNA methylation driven geneprognostic signaturetumor immuneprecision medicine
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Immunology
发表日期
2022-02-10
卷期
第 13 卷
页码
803962
DOI
10.3389/fimmu.2022.803962
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
China Postdoctoral Science Foundation [2020M682802]; National Natural Science Foundation of China [31972926, 81800665]; Guangdong Basic and Applied Basic Research Foundation [2020A1515111111]

作者

  • X

    Xiao, Mingjia (第一作者)

    2 · southern med univ

  • L

    Liang, Xiangjing

    southern med univ

查看全部 12 位作者收起作者
  • Y

    Yan, Zhengming

    2 · southern med univ

  • C

    Chen, Jingyang

    1 · southern med univ

  • Z

    Zhu, Yaru

    southern med univ

  • X

    Xie, Yuan

    2 · southern med univ

  • L

    Li, Yang

    2 · southern med univ

  • L

    Li, Xinming

    southern med univ

  • G

    Gao, Qingxiang

    1

  • F

    Feng, Feiling (通讯)

    1

  • F

    Fu, Gongbo (通讯)

    nanjing univ

  • G

    Gao, Yi (通讯)

    southern med univ · 2

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417